7 completed, 4 recruiting, 4 unknown, 2 terminated. 6 Not applicable, 4 Phase 2, 3 Phase 3, 1 Phase 1, 1 Phase 4.
Follow Chronic Kidney Disease Stage 3: new trials by email Literature Review of Chronic Kidney Disease Stage 3 trials Research Report on Chronic Kidney Disease Stage 3
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects of Replacing High Protein Foods in People With Chronic Kidney Disease Controlled dietary intervention - Chronic Kidney Disease Stage 3 | Not applicable | Recruiting | Indiana University | 15 | 2026-09-01 | 2026-08-11 |
| Vonafexor in Patients With Impaired Renal Function and Suspected MASH (Metabolic Dysfunction-associated Steatohepatitis) Vonafexor low dose, Vonafexor high dose - Chronic Kidney Disease Stage 2, Chronic Kidney Disease Stage 3 | Phase 2 | Terminated | Enyo Pharma | 10 | 2025-07-01 | 2026-04-23 |
| Clinical Effectiveness of MyNutriKidney® Counseling, Renal Diet App, Printed Nutrition Pamphlet - Chronic Kidney Disease Stage 3, Chronic Kidney Disease | Not applicable | Not yet recruiting | Universiti Putra Malaysia | 200 | 2025-07-01 | 2025-05-04 |
| Closed-Loop Impact on Chronic Kidney Disease in Type 2 Diabetes CamAPS HX, Standard insulin therapy with CGM - Type 2 Diabetes, Chronic Kidney Disease Stage 3 | Not applicable | Recruiting | Heba Al-Alwan | 76 | 2025-06-16 | 2026-02-12 |
| A Study to Investigate the Safety, Tolerability, and Preliminary Efficacy With AION-301 Administered by Intravenous Infusion Compared With Placebo Administered by Intravenous Infusion Investigational Intervention in Participants Aged 35 to 75 Years of Age With Chronic Kidney Disease (CKD) AION-301, Placebo - Chronic Kidney Disease Stage 3 | Phase 1 / Phase 2 | Recruiting | AION Healthspan, Inc. | 36 | 2025-01-23 | 2026-04-01 |
| Urinary Tubular Biomarkers for Chronic Kidney Disease Urinary tubular test panel - Chronic Kidney Disease Stage 3 | Recruiting | Erasmus Medical Center | 556 | 2025-01-01 | 2025-08-07 | |
| Preserving Kidney Function in Children With Chronic Kidney Disease Blood pressure, Urine protein - Chronic Kidney Disease Stage 2, Chronic Kidney Disease Stage 3 | Completed | Children's Hospital of Philadelphia | 20240 | 2023-09-22 | 2024-08-16 | |
| A Study to Investigate the Mechanistic Effects of Dapagliflozin Alone or in Combination With Balcinrenone, Compared to Balcinrenone and Placebo on Body Fluid and Electrolyte Handling and Energy Metabolism in Participants Over 50 Years of Age With Chronic Kidney Disease. Dapagliflozin 10mg Tab, Balcinrenone 50mg Capsule, Balcinrenone 100mg Capsule - Chronic Renal Failure, Mechanistic Effects of SGLT2 Inhibition and/ or MR Antagonism on Body Fluid and Electrolyte Homeostatis | Phase 2 | Completed | Klinikum Nürnberg | 103 | 2023-07-13 | 2026-04-27 |
| Safety, Feasibility and Efficacy of Sulforaphane (Avmacol Extra Strength) in Chronic Kidney Disease Sulforaphane (Avmacol Extra Strength), Placebo - Chronic Kidney Disease Stage 3, Chronic Kidney Disease Stage 4 | Phase 2 | Completed | University of Rochester | 96 | 2023-05-03 | 2026-05-18 |
| KPs Supplement for Inflammation, Oxidative Stress and Lipid Abnormalities in CKD Patients. KEFPEP®, Placebo - Chronic Kidney Disease Stage 3, Chronic Kidney Disease Stage 4 | Not applicable | Completed | National Chung Hsing University | 165 | 2023-02-03 | 2026-09-01 |
| Prospective Decision Impact Clinical Utility Trial of KidneyIntelX KidneyIntelX - Diabetic Kidney Disease, Chronic Kidney Diseases | Active not recruiting | Renalytix AI, Inc. | 2000 | 2021-11-01 | 2026-08-13 | |
| The Life Style Patterns and the Development Trend of Chronic Diseases in Healthy and Sub-healthy Groups Were Analyzed by Using Data-mining Techniques Chronic Kidney Disease Stage 1, Chronic Kidney Disease Stage 2 | Unknown | Far Eastern Memorial Hospital | 81108 | 2021-03-03 | 2022-05-10 | |
| Desidustat in the Treatment of Anemia in CKD Desidustat Oral Tablet, Darbepoetin Alfa - Chronic Kidney Disease Stage 3, Anemia | Phase 3 | Completed | Zydus Lifesciences Limited | 588 | 2019-07-20 | 2021-11-24 |
| Empowering Veterans to Communicate With Healthcare Providers CKD-Question Prompt Sheet - Chronic Kidney Disease Stage 3 | Not applicable | Terminated | Northwestern University | 8 | 2018-09-17 | 2022-03-18 |
| Vitamin K to Slow Progression of Cardiovascular Disease Risk in Hemodialysis Patients Vitamin K2 (menaquinone-7; 360-mcg/d), Placebo-Control - Cardiovascular Diseases, Chronic Kidney Disease Stage 3 | Not applicable | Unknown | Augusta University | 60 | 2017-09-13 | 2019-11-20 |
| Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar Control Placebo, Sotagliflozin - Type 2 Diabetes Mellitus, Chronic Kidney Disease Stage 3 | Phase 3 | Completed | Lexicon Pharmaceuticals | 787 | 2017-08-16 | 2021-06-25 |
| Effect of Phosphate Binders on FGF-23 With Concurrent Calcitriol Calcitriol, Calcium Carbonate - Chronic Kidney Disease Stage 3 | Phase 4 | Completed | Seoul National University Hospital | 30 | 2012-07-01 | 2013-02-18 |
| Primary Cardiovascular Risk Prevention With Aspirin in Chronic Kidney Disease Patients Aspirin - Chronic Kidney Disease Stage 4, Chronic Kidney Disease Stage 3 | Phase 3 | Unknown | Fundación de Ayuda a la Investigación sobre la Hipertensión, Riesgo Cardiovascular y Enfermedades Renales | 97 | 2010-05-01 | 2012-10-18 |
| Assessing Perceived Versus Actual Knowledge and Quality of Life in Pre-Dialysis Chronic Kidney Disease (CKD) Patients Chronic Kidney Disease Stage 3, Chronic Kidney Disease Stage 4 | Unknown | National University of Singapore | 400 | 2015-04-15 |
Renal Insufficiency, Chronic (19) · Diabetes Mellitus, Type 2 (2) · Disease Progression (2) · Proteinuria (2) · Anemia (1) · Bronchiolitis Obliterans Syndrome (1) · Cardiovascular Diseases (1) · Chronic Disease (1) · Communication (1) · Diabetic Nephropathies (1) · Hypertension (1) · Kidney Diseases (1) · Kidney Failure, Chronic (1) · Metabolic Syndrome (1) · Patient Participation (1)
Disease Attributes (19) · Female Urogenital Diseases (19) · Female Urogenital Diseases and Pregnancy Complications (19) · Male Urogenital Diseases (19) · Pathologic Processes (19) · Pathological Conditions, Signs and Symptoms (19) · Renal Insufficiency (19) · Urogenital Diseases (19) · Urologic Diseases (19) · Chronic Disease (18) · Kidney Diseases (18) · Nutritional and Metabolic Diseases (4) · Diabetes Mellitus (3) · Endocrine System Diseases (3) · Glucose Metabolism Disorders (3)
(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol (1) · Aspirin (1) · Blood Pressure (1) · Calcitriol (1) · Calcium Carbonate (1) · Continuous Glucose Monitoring (1) · Counseling (1) · Darbepoetin alfa (1) · Vitamin K 2 (1) · dapagliflozin (1) · desidustat (1) · menaquinone 7 (1) · sulforaphane (1)
AION Healthspan, Inc. (1) · Augusta University (1) · Children's Hospital of Philadelphia (1) · Enyo Pharma (1) · Erasmus Medical Center (1) · Far Eastern Memorial Hospital (1) · Fundación de Ayuda a la Investigación sobre la Hipertensión, Riesgo Cardiovascular y Enfermedades Renales (1) · Heba Al-Alwan (1) · Indiana University (1) · Klinikum Nürnberg (1) · Lexicon Pharmaceuticals (1) · National Chung Hsing University (1) · National University of Singapore (1) · Northwestern University (1) · Renalytix AI, Inc. (1)
United States (8) · Germany (3) · Spain (2) · Taiwan (2) · Argentina (1) · Brazil (1) · Canada (1) · Colombia (1) · France (1) · Hungary (1) · India (1) · Israel (1) · Italy (1) · Malaysia (1) · Mexico (1)
Adriana Marton, MD (1) · Chris Forrest, MD (1) · David W Lam, MD (1) · DrDeven Parmar, MD (1) · Elisa J Gordon, PhD, MPH (1) · Jung Mi Oh, Pharm.D. (1) · Michelle Denburg, MD (1) · Norman K Pollock, PhD (1) · Suman Wason, MD (1) · Yon Su Kim, M.D., Ph.D. (1)
PMID 25959301, PMID 29943364, PMID 32478665, PMID 32795256, PMID 33066603, PMID 35224730, PMID 36005278, PMID 36782093, PMID 40576086
2016 (1), 2023 (1), R01DK128677 (1)